Denintuzumab mafodotin (SGN-CD19A)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 15:05, 1 June 2014 by Jwarner (talk | contribs) (Created page with "=Mechanism of action= Antibody-drug conjugate =Preliminary studies= # '''Abstract:''' Andres Forero-Torres, Craig Moskowitz, Ranjana H. Advani, Bijal D. Shah, Ana Kostic, Tin...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

Antibody-drug conjugate

Preliminary studies

  1. Abstract: Andres Forero-Torres, Craig Moskowitz, Ranjana H. Advani, Bijal D. Shah, Ana Kostic, Tina M. Albertson, Larissa Sandalic, Baiteng Zhao, Michelle A. Fanale. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). J Clin Oncol 32:5s, 2014 (suppl; abstr 8505) link to original abstract
Retrieved from "https://hemonc.org/w/index.php?title=Denintuzumab_mafodotin_(SGN-CD19A)&oldid=4680"